6 results
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…
In the current phase 2 study we will investigate the efficacy of the combination of fulvestrant and alpelisib directly after progression on 1st or 2nd line therapy with fulvestrant with or without a CDK 4/6 inhibitor in patients with HR+HER2-…
Our primary objective is to translate an in non-human primate established online TUS protocol to humans. To this end, we will investigate how this protocol influences choice behaviour in humans, by stimulating the left and right FEF in a saccade…
Primary objective:* To demonstrate the efficacy of alpelisib as measured by the proportion of participants randomized to alpelisib with a response at Week 24 in at least one of the following groups:* Group 1 (>= 18 yr-old)* Group 2 (6 - 17 yr…
The primary objective is to assess the causal role of the human amygdala in fear learning, by indexing the impact of TUS targeting the amygdala on physiological markers of fear. The secondary objectives are to (1) discern the neuromodulatory effects…
Our primary objective is to elucidate the neurophysiologic effects of short-term TUS on deep brain circuits in humans. We will map the effects of TUS targeting the amygdala vs. two subregions of the thalamus (mediodorsal & pulvinar nucleus)…